UK – AbbVie’s Venclyxto gets NICE blood cancer backing

AbbVie’s Venclyxto (venetoclax) has been recommended for use by the National Institute of Health and Care Excellence (NICE) as a routine treatment for chronic lymphocytic leukaemia (CLL).

The oral B-cell lymphoma-2 (BCL-2) inhibitor has been indicated for use in combination with Roche’s Gazyvaro (obinutuzumab) for CLL patients who have not received prior treatment.

In particular, NICE has recommended Venclyxto plus Gazyvaro for routine NHS use in CLL patients with del(17p)/TP53 mutation and those without del(17p)/TP53 mutation for whom cyclophosphamide and rituximab (FCR) or bendamustine and rituximab (BR) are unsuitable…